TP53 and neoplasm: Low tumor mutational burden (TMB) and neoantigen (NA) load (30), downregulation of major histocompatibility complex (MHC)-1 in tumor cells (31), lysophosphatidic acid inhibition of type 1 interferon (32), an immunosuppressive environment in the ascites (33–36), immune evasion promoted by cancer driver mutations, including TP53 and phosphatase and tensin homolog deleted on chromosome ten (PTEN) (37), and aberrant oncogenic signaling pathways, all contribute to ICI resistance across various cancers (38).